913 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Was ASCO Quieter for Big Drug/Biotech Stocks This Year? http://www.zacks.com/stock/news/425444/was-asco-quieter-for-big-drug-biotech-stocks-this-year?cid=CS-ZC-FT-425444 Jun 06, 2019 - The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Why Merck (MRK) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/424931/why-merck-mrk-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-424931 Jun 05, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
10 Jaw-Dropping Numbers About Cancer Drug Development -- and What They Mean for Investors https://www.fool.com/investing/2019/06/05/10-jaw-dropping-numbers-about-cancer-drug-developm.aspx?source=iedfolrf0000001 Jun 05, 2019 - There's more good news with the fight against cancer than you might think.
Merck's Antibiotic Zerbaxa Gets FDA Nod for New Indication http://www.zacks.com/stock/news/424586/mercks-antibiotic-zerbaxa-gets-fda-nod-for-new-indication?cid=CS-ZC-FT-424586 Jun 04, 2019 - Merck (MRK) gets FDA approval for antibacterial medicine, Zerbaxa for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)
Bristol-Myers (BMY) Presents Multiple Data on Opdivo at ASCO http://www.zacks.com/stock/news/424416/bristol-myers-bmy-presents-multiple-data-on-opdivo-at-asco?cid=CS-ZC-FT-424416 Jun 04, 2019 - Bristol-Myers (BMY) announces data from multiple studies on immuno-oncology drug, Opdivo, at ASCO.
3 Drug Stocks That Could Win From Key FDA Approvals in June https://www.fool.com/investing/2019/06/04/3-drug-stocks-that-could-win-from-key-fda-approval.aspx?source=iedfolrf0000001 Jun 04, 2019 - Two hope to pick up additional indications for existing blockbuster drugs, while another could score a big victory for a new drug.
Company News For Jun 4, 2019 http://www.zacks.com/stock/news/424463/company-news-for-jun-4-2019?cid=CS-ZC--424463 Jun 04, 2019 - Companies In The News Are: EE,CY,AMGN,MRK
Why Cancer-Fighting Stocks & ETFs Are Soaring http://www.zacks.com/stock/news/424108/why-cancer-fighting-stocks-etfs-are-soaring?cid=CS-ZC-FT-424108 Jun 03, 2019 - The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Novartis (NVS) Announces Various Data Presentations at ASCO http://www.zacks.com/stock/news/424089/novartis-nvs-announces-various-data-presentations-at-asco?cid=CS-ZC-FT-424089 Jun 03, 2019 - Novartis (NVS) announces a number of data presentations at the ASCO 2019 annual meeting.
AstraZeneca's Imfinzi Shows Long-Term Benefits in Lung Cancer http://www.zacks.com/stock/news/423951/astrazenecas-imfinzi-shows-long-term-benefits-in-lung-cancer?cid=CS-ZC-FT-423951 Jun 03, 2019 - AstraZeneca (AZN) presents follow-up data on Imfinzi from late-stage PACIFIC study evaluating it in lung cancer patients.

Pages: 1...345678910111213...92

<<<Page 8>